1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Albany International said it completed its strategic review of the Amelia Earhart Drive facility in Salt Lake City and will keep the site, following an amended CH-53K contract with Sikorsky and new business wins. The company also reversed part of a forward loss reserve from the third quarter of 2025 and raised its third-quarter 2026 adjusted EPS outlook to $1.40 to $1.50, while its net revenue outlook was unchanged.
The company will retain the Amelia Earhart Drive facility and end the strategic review; Guggenheim Securities served as its financial advisor.
It reversed a portion of the forward loss reserve recognized in Q3 2025 on the CH-53K contract, and the contract modification is expected to generate positive cash flow beginning in 2027.
Q3 2026 adjusted EPS outlook rose from $0.60 to $0.70 to $1.40 to $1.50; Q3 consolidated net revenue outlook remains $320 million to $330 million.
Q4 2026 outlook calls for consolidated net revenue of $325 million to $335 million and adjusted EPS of $0.65 to $0.75; investor webcast on September 2, 2026 at 8:30 a.m. ET.
Dell reported fiscal second-quarter 2027 results for the quarter ended July 31, 2026, with net revenue of $46,971 million, up 58% year over year, and diluted EPS of $6.34, up 273%. Dell raised its full-year FY27 revenue guidance to $192.0 billion from $167.0 billion and its GAAP diluted EPS guidance to $24.37 from $17.31, while cash flow from operations fell 13% in the quarter to $2.2 billion.
Q2 net revenue of $47.0 billion, up 58% year over year; GAAP diluted EPS of $6.34, up 273%
Full-year FY27 revenue guidance raised to $192.0 billion from $167.0 billion; GAAP diluted EPS guidance $24.37, up from $17.31
Q3 FY27 guidance: revenue of $49.0 billion and GAAP diluted EPS of $6.10
Record $4.3 billion returned to shareholders in Q2; quarterly dividend of $0.63 per share payable Oct. 30 to holders of record as of Oct. 20
Sportsman's Warehouse reported second-quarter results for the thirteen weeks ended August 1, 2026, with net sales up 0.6% to $295.6 million and a net loss of $4.4 million, compared with $7.1 million a year earlier. The company reaffirmed its full-year 2026 guidance for same store sales and adjusted EBITDA. For shareholders, sales and loss improved year over year, and inventory and net debt were reduced, while same store sales were flat for the quarter.
Net sales rose 0.6% to $295.6 million; same store sales were flat, with Hunting and Shooting Sports up 6.7%.
Net loss narrowed to $4.4 million, or $(0.11) per diluted share, from $7.1 million, or $(0.18), a year earlier.
Adjusted EBITDA was $8.7 million, compared with $8.3 million in the second quarter of fiscal 2025.
Fiscal 2026 guidance was reiterated: same store sales down 1.0% to up 2.0% and adjusted EBITDA of $30 million to $36 million. Total inventory fell $44.5 million year over year, and net debt was $167.0 million.
Credo Technology Group reported first-quarter fiscal 2027 revenue of $479.0 million, up 114.7% from a year earlier and 9.6% from the prior quarter. GAAP net income was $129.4 million, or $0.67 per diluted share, down from $169.1 million in the prior quarter but up from $63.4 million a year earlier. The company guided second-quarter revenue to $525 million to $535 million.
Q1 fiscal 2027 revenue was $479.0 million, up 114.7% year over year and 9.6% quarter over quarter.
GAAP diluted EPS was $0.67, compared with $0.88 in the prior quarter and $0.34 a year earlier; non-GAAP diluted EPS was $1.20, compared with $1.16 in the prior quarter.
Q2 fiscal 2027 outlook calls for revenue of $525 million to $535 million and non-GAAP gross margin of 67.0% to 69.0%.
Ending cash and short-term investments totaled $764.3 million as of August 1, 2026.
Lexaria (AU) Pty Ltd, a wholly owned subsidiary of Lexaria Bioscience Corp., received an Australian R&D tax incentive credit on August 28, 2026. The credit, about USD$2.6 million, relates to research and development costs for its Australian clinical study GLP-1-H24-4 and has been deposited into the subsidiary's Australian bank account for additional research and development in Australia.
Credit received August 28, 2026 from the Australian Tax Office: AUD$3,666,611.98 (USD$2.6 million)
Credit tied to research and development costs for clinical study GLP-1-H24-4
Funds deposited in Lexaria (AU) Pty Ltd's Australian bank account for additional R&D opportunities in Australia
MiniMed reported first-quarter fiscal 2027 net sales of $843 million, up 16.6% from $723 million a year earlier, and reported net income of $0 compared with a loss of $16 million. The company raised its fiscal 2027 organic revenue growth guidance to approximately 10.5% from approximately 10%, while reaffirming its adjusted EBITDA margin guidance of approximately 16%.
Net sales were $843 million vs. $723 million; U.S. net sales grew 13.1% to $240 million and international grew 18.1% to $603 million.
Net income attributable to the company was $0 (EPS $0.00) vs. a loss of $19 million (EPS -$0.08) a year earlier.
FY27 organic revenue growth guidance raised to approximately 10.5% from approximately 10%; the figure includes a 1.0% to 1.5% benefit from an extra week in Q1.
Adjusted EBITDA margin guidance of approximately 16% was reaffirmed; a $2 million litigation benefit was recorded vs. a $17 million charge a year earlier.
Medtronic reported first quarter fiscal 2027 revenue of $9.8 billion, up 13.7% as reported and organically, and GAAP diluted EPS of $1.14 versus $0.81 a year earlier. The company raised its fiscal 2027 organic revenue growth guidance to 7.25% to 7.75% and its non-GAAP diluted EPS guidance to $5.94 to $6.00, both measures improving on the prior outlook.
Q1 revenue of $9.756 billion, up 13.7% as reported and organically; the extra fiscal week benefited organic growth by approximately $570 million, per the company
Q1 GAAP diluted EPS of $1.14, up 40.7%; non-GAAP diluted EPS of $1.45, up 15.1%
FY27 organic revenue growth guidance raised to 7.25% to 7.75% from 6.75% to 7.25%
FY27 non-GAAP diluted EPS guidance raised to $5.94 to $6.00 from $5.90 to $6.00
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.